NCI’s cancer screening trials may be falling victim to the COVID-19 pandemic.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
NCI will form an ad hoc committee to review screening trials
The future of ECOG-ACRIN's slowly-accruing TMIST is in question
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
An estimated 5,200 of HHS employees have been fired during the course of this week. Since the firings are ongoing, no final tally of their extent exists. At this writing, approximately 1,200 of the fired HHS employees were working at NIH, about 700 at FDA, and 750 at CDC.
Cancer data quoted in President Trump’s executive order last week have raised eyebrows among experts in cancer epidemiology.
Today, our world is small. It feels smaller all the time. In a few hours we can get to any point on the globe.
As cancer clinicians, we spend years learning how to think objectively and rationally when supporting patients who have responded to a cancer diagnosis with anger and fear.
Nearly 30 years ago, while completing an assignment for his master’s degree in public health, Brian Rivers discovered he had a family history of prostate cancer.
